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The king of herbs, Panax ginseng, has been used widely as a therapeutic agent vis-a`-vis its active pharmacological and physiological
effects. Based on Chinese pharmacopeia Ben Cao Gang Mu and various pieces of literature, Panax ginseng was believed to exert
active vascular protective effects through its antiobesity and anti-inflammation properties. We investigated the vascular protective
effects of ginseng by administrating ginseng extracts to rats after the induction of diabetes. We found that Panax ginseng can
restore diabetes-induced impaired vasorelaxation and can reduce serum triglyceride but not cholesterol level in the diabetic rats.
The ginseng extracts also suppressed the expression of atherosclerosis-related genes and altered the expression of lipid-related genes.
The results provide evidence that Panax ginseng improves vascular dysfunction induced by diabetes and the protective effects may
possibly be due to the downregulation of atherosclerosis-related genes and altered lipid metabolism, which help to restore normal
endothelium functions.
1. Introduction
Panax ginseng is one of the most commonly used Chinese
medicine and research targets. The major active compo-
nents of Panax ginseng are ginsenosides which can be sub-
divided into three groups according to their basic structures:
protopanaxadiol (PPD) type (e.g., Rb1, Rb2, Rc, Rd, Rg3,
and Rh2), protopanaxatriol (PPT) type (e.g., Re, Rf, Rg1,
Rg2, and Rh1), and oleanolic acid (e.g., Ro). Ginsenosides
appear to be responsible for most of the activities of ginseng
including antioxidation, anti-inflammation, and anticancer
[1]. A review by Karmazyn et al. has found that the yearly
ginseng-related publication has been increasing exponen-
tially from 1950 to 2010. They also reported that Panax
ginseng played a protective role in the cardiovascular system
[2]. This suggested the beneficial properties of ginseng on
cardiovascular diseases in both experimental and clinical
settings.
Atherosclerosis is one of the most common cardiovas-
cular diseases and can remain asymptomatic for decades. In
the mid 1970s, Russel Ross developed the popular “response
to injury” theory by postulating that atherosclerosis begins
with injuries on the endothelium, followed by adhesion
and aggregation of platelets [3]. At about the same time,
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Robert F. Furchgott, the Nobel Prize Laureate in Physi-
ology or Medicine in 1998, discovered that acetylcholine
induces endothelium-dependent relaxation in normal aortic
tissue [4]. Upon early onset of atherosclerosis, endothelium
can remain morphologically intact though inflammatory
responses are triggered. Since then, numerous researches
have been conducted to investigate the mechanisms of
atherosclerosis to mitigate the associated diseases including
adhesion of lipid-laden macrophages and smooth muscle
cells which could finally result in endothelial denudation
[5]. Besides, Hansson’s research groups have reported that
high level of total cholesterol and low density lipoprotein
accumulated in the intima of the arteries, with the attack of
myeloperoxidase and lipoxygenases, or by reactive oxygen
species [6, 7] could also cause the early onset of atheroscle-
rosis.
The primary objective of this study is to evaluate the
protective effects of Panax ginseng on diabetes mellitus,
a pathological condition which links to endothelial dys-
functions, through investigating the physiological parame-
ters such as blood glucose, blood cholesterol, insulin, and
advanced glycation end product in diabetic rat models.
Furthermore, the changes of atherosclerosis-related genes
expression in diabetic rats are also investigated after ginseng
administration. The findings may help in the development
of successful therapeutic interventions for atherosclerotic
cardiovascular disease.
2. Materials and Methods
This study follows “The International Guiding Principles
for Biomedical Research Involving Animals,” The Hong
Kong Code of Practice for Care and Use of Animals for
Experimental Purposes (2004). All experimental procedures
were conducted according to the Animals (Control of Exper-
iments) Ordinance of the Department of Health, HKSAR
(Animal Licenses ID: (11-6) DH/HA&P/8/2/6 Pt.2; (10-4)
DH/HA&P/8/2/6 Pt.1; (10-9) DH/HA&P/8/2/6 Pt.1). All ani-
mal studies were performed in facilities approved by the
Animal Ethics Committee of the Chinese University of Hong
Kong (10/028/MIS).
2.1. Animals. Male Sprague-Dawley (SD) rats weighing 150–
200 grams were housed in room under standard vivarium
conditions with 12 hour light/dark cycle. Throughout the
experimental period, animals were fed with standard rodent
chow and water available ad libitum. The animals were accli-
matized to the laboratory conditions for 10 days prior to the
inception of experiments. Experimental diabetic condition
was induced in rats by a single intraperitoneal injection (i.p.)
of streptozotocin (75mg/kg body weight) freshly dissolved in
cold citrate buffer (0.1M), while the normal control group
was injected with citrate buffer only. Blood samples were
collected from tail veins of overnight-fasted rats three days
after streptozotocin administration. Rats with blood glucose
level higher than 16.7mmol/dL were selected for experiment.
The experimental rats were divided into seven groups:
(1) normal control rats administered with water, (2) dia-
betic group of rats administered with water, (3) dia-
betic group administered with intraperitoneal injection of
insulin, (4) diabetic group fed with PPT-type of ginseng
(10mg/kg/day), (5) diabetic group fed with PPT-type of
ginseng (30mg/kg/day), (6) diabetic group fed with PPD-
type of ginseng (10mg/kg/day), and (7) diabetic group fed
with PPD-type of ginseng (30mg/kg/day). The dosage of
insulin followed a protocol developed by Kuo et al. [8], and
water or drugs were administered for a total of 14 consecutive
treatment days. Both PPD and PPT were administered orally
in the form of aqueous suspension. Rats were anaesthetized
by Ketamine-Rompun mixture (7.5 : 1), and blood was col-
lected from the heart for further analysis. The animals were
then sacrificed immediately by cervical dislocation. Aortae
were removed and trimmed for tissue bath experiment. Other
rat tissues including brain, heart, liver, spleen, eye, kidney,
and aorta were immediately removed and instantly soaked in
liquid nitrogen and stored at −70∘C for further biochemical
analysis.
2.2. Ginseng Preparation. Panax ginseng extractwas prepared
as described in Zhu et al. [9], which meets the requirement
of the Chinese Pharmacopoeia and Hong Kong Standard
of Chinese Materia Medica. Standardized ginseng extract
(RSE) was prepared by ethanol extraction. The residue was
then dissolved in water and partitioned successively with
petroleum ether, EtOAc, and n-BuOH to give the petroleum-
ether-soluble, EtOAc-soluble, and n-BuOH-soluble fractions.
The n-BuOH extract was subjected to column chromatog-
raphy eluted with a CHCl
3
/MeOH gradient. Fractionated
samples were combined and obtained according to the thin
layer chromatography analysis. All samples were then stored
in desiccated condition until further use. High performance
liquid chromatography was used to confirm the identity of
our samples with the standard ginsenosides (HPLC purity
>98%) purchased from Chengdu Scholar Bio-Tech Co. Ltd.
(Chengdu, China) or National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China).
The contents of ginsenosides Rg1, Re, Rb1, Rc, Rb2, and
Rd were 290.9, 339.6, 246.3, 231.3, 136.0, and 84.5mg/g,
respectively (Figure 1 and Table 1).
2.3. Measurement of Contractile and Relaxant Responses
in the Rat Aortic Rings. Similar procedures were followed
according to the protocol as described by Chan and Fiscus
2002 [10]. Briefly, thoracic aortae were isolated by cutting
from the aortic arch to the diaphragm, resulting in a length
of 30–40mm tissue. In order to prevent physical damage
of endothelium by forceps, the parts from the aortic arch
were not used for experiment. Fat tissues were trimmed off
from the aortae and before it was cut into 3mm segments
rings. The segments were then mounted carefully between
two platinum hooks in 10mL organ baths containing Krebs
buffer (KRB) maintained at 37∘C bubbled with 95% O
2
–5%
CO
2
continuously. Following a 30min equilibration period of
resting tension of 1 gram, cumulative doses of phenylephrine
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Figure 1: HPLC fingerprint of PPT-type (Panel (a)) and PPD-type (Panel (b)) ginseng extract used in current study. Instruments.AnHP 1100
system (Hewlett-Packard, Wilmington, DE) consisting of a G1312A binary pump, a G1329A automatic sample injector, and a G1315A diode
array detector was used to performHPLC analysis. Sample Preparation.Approximately 0.20 g powdered ginseng was accurately weighed into
a 50mL conical flask, and 10mL 70% methanol was added. The suspension was sonicated for 30min, and the sample solution was filtered
through a 0.45𝜇mfilter and used as the test solution for quantitative analysis of ginsenosides in Radix Ginseng. Chromatographic Conditions.
HPLC analysis of Radix Ginseng was performed on an Alltima C
18
HPLC column (4.6mm × 250 mm, 5 𝜇m) at 25∘C with a sample injection
volume of 20 𝜇L. The mobile phase was a gradient elution of KH2PO4 buffer (2mmol/L, pH 6.8) and acetonitrile, starting isocratically with
21% acetonitrile for 15min and increasing to 38% acetonitrile over 55min.The flow rate of the mobile phase was 1.0 mL/min, and the detector
wavelength was 203 nm.
(1× 10−9Mto 1× 10−5M)were added in each aortic ring. After
the addition of phenylephrine, the aortic rings were washed
with fresh and bubbled KRB solution every 10 minutes over
a 30-minute period. A single dose of phenylephrine at 1 ×
10−7Mwas added until the aortic ringsmaintained 50 percent
of maximum tension. Doses of acetylcholine (1 × 10−9M to
1×10
−5M)were added cumulatively to check the endothelial
functions. All of the doses were added after the responses
reached plateau.
2.4. Blood Profile of the Experimental Rats. Serum tests
for total cholesterol (TC), triglyceride (TG), low density
lipoprotein (LDL), and high density lipoprotein (HDL) were
conducted in The State Key laboratory for Chinese Medicine
and Molecular Pharmacology of the Hong Kong Polytechnic
University. Terminal colorimetric analysis method was used
for quantification of TC, TG, LDL, andHDL, respectively.The
tests were conducted with ECHO automatic biochemistry
analyzer (Logotech, Italy) and UV2800 spectrophotometer
(Unico, Shanghai).
Blood glucose level was measured using glucometer
(Elite, Bayer Corporation, USA). Serum insulin and glycation
end products weremeasured using kits purchased fromMilli-
pore (EZRMI-13K) and Cusabio (CSB-E08140r), respectively.
2.5. 𝑅𝑇2 Profiler Rat Atherosclerosis PCR Array Analysis.
Aortic samples for PCR array analysis were used to obtain the
total RNA by Qiagen RNeasy Mini Kit (Catalogue number:
PARN-038A, Qiagen). This pathway specific RT-PCR array
was used to evaluate the potential alterations of related genes
after PPD-type and PPT-type treatments (30mg/kg/day)
in rats. The atherosclerosis array comprised of 87 genes
selected based on their involvement in regulating vascular
and endothelial cell homeostasis or inflammation. There
were 5 housekeeping genes served as positive controls. Total
RNA was reverse transcripted using the RT2 First Strand
Kit. Real-time PCR reactions were carried out on ABI 7500
(Applied Biosystems) using the RT2 SYBR Green qPCRMas-
termix (Qiagen) according to manufacturer’s instructions.
Data analysis was performed using the Qiagen’s integrated
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Table 1: Contents of ginsenosides in the prepared PPT-type and PPD-type ginsenosides.
Sample Ginsenosides Content (mg/g) Percentage
PPT-type ginsenosides Rg1 290.9 29.09%
Re 339.6 33.96%
PPD-type ginsenosides
Rb1 246.3 24.63%
Rc 231.30 23.13%
Rb2 136.0 13.61%
Rd 84.5 8.45%
web-based software package for the PCR Array System,
which automatically performs all ΔΔCt based fold-change
calculations from raw threshold cycle data.
2.6. Statistical Analysis. All values are expressed as mean ±
standard error of mean (SEM). The significant differences
between the young and aged groups in the isolated tissue
experiments were analyzed using one way ANOVA with
Newman-Keuls multiple comparison as post hoc test in the
statistical package (Graphpad prism v6.0). A 𝑃 value less
than 0.05 was considered to be significant. The mean values
were obtained from at least 5 animals or 3 DNA samples per
treatment group.
3. Results
3.1. Ginseng Extracts Restore High Glucose-Induced Endothe-
lial Dysfunction. Acetylcholine (ACh) causes vasodilation
by activation of endothelial nitric oxide synthase and
prostaglandin production. The aortic tissue was chal-
lenged with acetylcholine (1× 10−9M–1× 10−5M) and caused
concentration-dependent relaxations in aortic rings from
young rats. Normal rats showed 100% relaxation (restored
the contracting state to resting state) at maximum dose 1 ×
10
−5M, while the response was only 62.5% of the relaxation
in the diabetic rats (Figure 2(a)), showing an impairment
of the endothelium. For positive control, diabetic rats were
injected with insulin and the normal vasorelaxation was
maintained (Figure 2(b)). After feeding PPD-type and PPT-
type ginseng extracts for two weeks, the impaired vasore-
laxation due to high glucose level was restored (Figures
2(c) to 2(f)), indicating that the endothelial functions were
maintained under the diabetic conditions for the ginseng-fed
groups.
3.2. Blood Profile, Body Weight, Distribution of Visceral Adi-
pose Tissue, and Organs Weight of the Experimental Rats. In
this study, blood glucose, insulin, advanced glycation end
products, serum total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL), and triglyceride were
examined. Except for normal and insulin injected positive
control group, all of the diabetic groups were considered
to be diabetic (blood glucose >16.7mmol/dL) and with a
significant reduction of insulin level (Figure 3(a)). There are
no statistical differences between the ginseng-fed or nonfed
diabetic groups for blood glucose, insulin, serum total choles-
terol, HDL, and LDL (Figures 3 and 5(a)–5(c)), indicating
the ginseng extracts have no improvement on hyperglycemic
conditions or alternation of cholesterol levels. However, there
is a slight decrease in the level of glycation end products
(Figure 4), when the diabetic group was fed with PPT-type
of ginseng at a dosage of 30mg/kg/day. In addition, there
was also significant decrease in serum triglyceride level for
all ginseng-fed groups, which indicated that both PPD-type
and PPT-type are effective in lowering serum triglyceride
(Figure 5(d)). Visceral adipose tissue is associated with fatty
acid metabolism. The distribution of visceral adipose tissue
surroundingmesenteric arteries was shown in Figure 6.More
visceral adipose tissue was found in control group when
compared to the diabetic group. However, more visceral
adipose tissue was observed in diabetic rats after feeding with
PPD-type and PPT-type of ginseng extracts. The body mass
and organmass are the health indicators for the experimental
rats. Figure 7 showed the body and organ weight of the
experimental rats. The body weight of the insulin-injected
diabetic groups is slightly larger than other groups. Among
all organsmeasured (liver, pancreas, heart, adrenal gland, and
kidneys), the PPD-type fed diabetic groups have significantly
smaller adrenal glands than diabetic group (𝑃 < 0.05).
3.3. Ginseng Extract Suppresses the Expression of Athero-
sclerosis-Related Genes. PCR array analysis showed the fold
change of atherosclerosis-related gene expression (Figure 8
and Table 2) for different treatment groups. When compared
to normal control group, diabetic groups showed an upreg-
ulation on several atherosclerosis-related gene expressions,
which indicate an increased risk of atherosclerosis. Besides,
the gene expressions related to inflammations including
adhesion molecules such as selectin (platelet) and ICAM1
andmacrophage activation including chemokine (C-C)motif
ligand 2 (CCl-2), chemokine (C-X-C) motif ligand 1 (CxCl-
1), interleukin 1 receptor 2 (IL1-R2), interleukins (IL3, IL4
and IL5), and tumor necrosis factor-𝛼 (TNF-𝛼) were down-
regulated. Apart from genes related to inflammation, other
genes involved in the development of atherosclerosis were
also checked. Apoptotic genes, such as Bid as well as genes
responsible for vascular endothelial cells and vascular smooth
muscle cell proliferation andmigration (including vonWille-
brand factor homolog, heparin-binding EGF-like growth
factor, and thrombospondin 4), were also downregulated in
ginseng-fed diabetic groups. On the other hand, lipid-related
genes expression including apolipoprotein E (ApoE), lipase,
and peroxisome proliferator-activated receptor (PPAR) 𝛾
were increased in the ginseng-fed groups.
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Table 2: PCR array analysis of expression change in selected atherosclerosis-related genes.
Gene name
Fold change#
Diabetes PPD-fed diabetic group(30mg/kg/day)
PPT-fed diabetic group
(30mg/kg/day)
Adhesion molecules
Selectin (platelet) +2.33 +1.18 +1.29
Intercellular adhesion molecule 1 +2.06 +1.46 +1.46
Macrophages
Chemokine (C-C) motif ligand 2 +2.49 +0.56 +0.47
Chemokine (C-X-C) motif ligand 1 +3.19 +0.89 +0.58
Interleukin 1 receptor, type II +3.28 +1.22 +1.38
Interleukin 3 +0.95 +0.48 +0.82
Interleukin 4 +1.23 +0.53 +0.83
Interleukin 5 +1.08 +0.78 +0.79
Tumor necrosis factor-𝛼 +1.56 +1.31 +1.03
Lipid metabolism
Apolipoprotein E +1.53 +2.95 +2.50
Lipase +13.85 +24.93 +8.82
Peroxisome proliferator-activated receptor-𝛾 +2.54 +5.83 +2.06
Cell growth and migration
Fibrinogen beta chain +0.93 +0.43 +0.62
von Willebrand factor homolog +4.45 +3.33 +2.99
Heparin-binding EGF-like growth factor +2.53 +1.95 +2.04
Laminin 𝛼 1 +0.93 +0.64 +0.61
Extracellular matrix (ECM)
Fibronectin +2.91 +1.94 +1.66
Apoptosis
Bcl2-like 1 +0.73 +0.75 +0.83
BH3 interacting domain death agonist +1.45 +1.25 +1.23
#Fold changes (comparing to control group, fold change = 1) are calculated according to manufacturer’s analysis software.
In general, the ginseng-fed diabetic groups showed a
decreased expression on atherosclerosis-related genes, which
indicates the decreased risk of atherosclerosis after ginseng
treatments.
4. Discussion
Endothelium controls vascular tone through the production
of vasodilator mediators, endothelium-derived relaxing fac-
tors (EDRF), which act on vascular smooth muscle cells.
The EDRF comprise nitric oxide (NO), prostacyclin, and an
elusive endothelium-derived hyperpolarizing factor (EDHF).
Multiple mechanisms lead to endothelial dysfunction [11,
12], and endothelial dysfunction plays a key role in the
pathogenesis of vascular diseases. Hyperglycemia is linked to
the pathogenesis of diabetic complications involving alterna-
tions of intracellular metabolism and formation of advanced
glycation end products.
The attenuated endothelium-dependent vasodilations
have been demonstrated in various vascular tissues of dia-
betic animal model [13]. In the present study, we examined
the endothelial functions using the physiological isolated
tissue bath setup and found that the high glucose-impaired
vasodilations were restored after ginseng extracts treatment
(Figure 2). The result indicates that ginseng extract plays a
protective role in restoring normal endothelial functions in
diabetic models. Different molecular mechanisms have been
demonstrated to cause the vascular dysfunctions. Reports
have suggested that hyperglycaemia-induced endothelial dys-
function is due to activation of protein kinase C (PKC)
[14], inhibition of endothelial nitric oxide synthase [15, 16],
early and advanced nonenzymatic glycation, and oxidative
stress [17–19]. In atherosclerotic conditions, up-regulation
of adhesion molecules, increased cytokine secretion, apop-
tosis, enhanced low-density lipoprotein oxidation, platelet
activation, and vascular smooth muscle cell proliferation
and migration are always observed [20–22]. Therefore, com-
pounds that are able to modulate atherosclerosis and main-
tain normal endothelial functions are highly desirable.
Although the levels of LDL, TC, HDL, and insulin in
diabetic group were not significantly different when com-
pared with the ginseng-fed groups, ginseng-fed diabetic
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Figure 2: Ginseng extracts restore acetylcholine-induced endothelium dependent vasorelaxation. After the addition of phenylephrine, doses
of acetylcholine (1 × 10−9M to 1 × 10−5M) were added cumulatively to check the endothelial functions. Control group showed an attenuation
of acetylcholine-induced vasorelaxation (Panel (a)). The insulin injected diabetic group (Panel (b)), PPT-type (30mg/kg/day) fed diabetic
group (Panel (c)), PPT-type (10mg/kg/day) fed diabetic group (Panel (d)), PPD-type (30mg/kg/day) fed diabetic group (Panel (e)), and
PPD-type (10mg/kg/day) (Panel (f)) fed diabetic group showed restoration of the attenuated vasorelaxation. Results were expressed as the
mean ± standard error; ∗𝑃 < 0.05 for the indicated comparisons.
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Figure 3: Blood glucose level (Panel (a)) and serum insulin level (Panel (b)) of control, diabetic, and ginseng extract-fed diabetic groups.The
bar indicates standard error; ∗𝑃 < 0.05 for the indicated comparisons versus diabetic group.
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Figure 4: Level of advanced glycation end product in serum of
control, diabetic, and ginseng extract-fed diabetic groups. Results
were expressed as the mean ± standard error; ∗𝑃 < 0.05 for the
indicated comparisons versus diabetic group.
groups showed a decrease in serum triglyceride level after
ginseng feeding (Figure 5(d)). Increased levels of serum
triglyceride and free fatty acids are common features of
diabetic dyslipidemia [23]. There are direct corelations of
serum triglyceride with triglyceride-associated nonalcoholic
fatty liver disease (NAFLD), which is a multifactorial syn-
drome linked with cardiovascular diseases [24]. To fur-
ther investigate the underlying mechanisms of the altered
triglyceride metabolism, we performed PCR array analysis
to examine the changes of gene expressions in rat aorta
after ginseng treatment. By comparing normal, diabetic, and
ginseng-fed diabetic groups, we have studied the change of
expression in 87 different atherosclerosis or lipid metabolism
related genes. Several lipid metabolism related genes such
as ApoE, lipase, and PPAR-𝛾 are upregulated in the aorta
of ginseng extract-fed groups when compared to diabetic
control group, showing the beneficial effects of ginseng. ApoE
is responsible for catabolism of triglyceride-rich lipoprotein
and cardiovascular diseases and was found to be related to
proinflammatory cytokines [25]. On the other hand, up-
regulated gene expression of lipase leads to increase process
of dietary lipids (e.g., triglyceride) which may explain the
decreased triglyceride levels. PPAR-𝛾 is up-regulated by PPD,
and it is the target of thiazolidinediones, the drugs used in
treatment of diabetes mellitus. The upregulations of these
genes provide possible explanation to the lowered triglyceride
levels.
There is no statistically significant difference in body
weight among the normal and the diabetic groups, possibly
due to large variations of body weights of diabetic groups.
Interestingly, the insulin-injected diabetic control group has
significant weight gain (Figure 7(a)). The weight gain in the
insulin-injected diabetic group has been reported by Jansen
et al. in 2010 [26], which may be due to insulin therapy.
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Figure 5: Serum levels of total cholesterol (Panel (a)), LDL (Panel (b)), HDL (Panel (c)), and triglyceride (Panel (d)) in control, diabetic, and
ginseng extract-fed diabetic groups. Results were expressed as the mean ± standard error; ∗𝑃 < 0.05 for the indicated comparisons versus
diabetic group.
The weight of adrenal glands (Figure 7(b)) is significantly
smaller in the groups fed with PPD-type groups of ginseng
extract except the liver (Figure 7(c)); other organs including
pancreas, heart, and kidneys are not significantly different in
weight among all diabetic groups (Figures 7(d)–7(f)).
Known to be responsible for “fight-or-flight” response,
the size of adrenal glands reflects adrenocorticoid secretion
[27], and adrenal enlargement is directly related to stress [28]
like diabetes mellitus [29]. Interestingly, though insulin ther-
apy is the knownmost effectivemethod for diabetes, it cannot
reverse adrenal gland enlargement.This may due to intensive
injection of insulin which imposed stress on the rats. How-
ever, PPD-type extract, at both dosages of 10mg/kg/day and
30mg/kg/day, can reduce the size of enlarged adrenal glands
in diabetic groups significantly (Figure 7(b)).
It has been shown with evidence that endothelial apop-
tosis might be a major cause of plaque erosion [30]. If
there is endothelial apoptosis, lipid-laden foam cells derived
frommacrophages produce phospholipid oxidation products
(OX-PL) and play a role in atherosclerosis. There are two
forms of atherosclerotic plaques, (1) stable plaque, which is
made up of thick fibrous cap isolating small lipid core and
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(c) (d)
Figure 6: Distribution of visceral adipose tissue surrounding mesenteric arteries. The mesenteric bed from normal rats (Panel (a)) is
surrounded by adipose tissue, whereas the mesenteric bed of diabetic rats (Panel (b)) is not surrounded by any adipose tissue. The PPD-
type fed diabetic group (Panel (c)) and PPT-type fed diabetic group (Panel (d)) have comparatively more adipose tissue than the diabetic
group.
associated with low risk of thromboembolic complications,
and (2) unstable plaque, which is a large lipid core covered
by thin fibrous cap and prone to rupture and thrombus
formation and associated with high risk of thromboembolic
complications [31]. Hence, in addition to the decrease in
triglyceride levels and changes in lipid metabolism related
genes expression, the decrease in apoptosis-related genes
such as Bcl2-like 1 and Bid may also help to reduce risk
of atherosclerosis and restore normal aorta vasorelaxation.
Figure 6 shows that there is more visceral adipose tissue
in the ginseng-fed groups, and the observation may be
related to the altered lipid metabolism in diabetic conditions.
It is known that visceral adipose tissue is linked to fatty
acid metabolism [32]. However, as most of the researches
focus on the adverse effects of visceral adipose tissue which
is a common observation in obesity, we cannot find any
evidence to explain the current phenomenon. However, it has
been found that ginsenoside Rb1 promotes adipogenesis in
3T3-L1 cells by enhancing PPAR-𝛾2 and C/EBP-𝛼 functions
[33]. According to our present data on increased PPAR-𝛾
expression, we believe that ginseng extract can modulate
lipid metabolism in the diabetic condition through altered
gene expression, which may result in an increased amount of
visceral adipose tissue.
Furthermore, similar observation has been reported by a
recent paper published by Liu et al. [34], who showed that
10 Evidence-Based Complementary and Alternative Medicine
0
100
200
300
400
Bo
dy
 w
ei
gh
t (
g)
∗∗∗ ∗∗∗P < 0.001
(a)
0.00
0.05
0.10
0.15
W
ei
gh
t o
f a
dr
en
al
 g
la
nd
s (
g)
∗P < 0.05
∗ ∗
(b)
0
5
10
15
20
W
ei
gh
t o
f l
iv
er
 (g
)
∗P < 0.05
∗
(c)
0.0
0.5
1.0
1.5
W
ei
gh
t o
f p
an
cr
ea
s (
g)
(d)
0.0
0.5
1.0
1.5
W
ei
gh
t o
f h
ea
rt
 (g
)
N
or
m
al
D
ia
be
te
s
In
su
lin
 in
je
ct
ed
 co
nt
ro
l
PP
T-
ty
pe
10
m
g/
kg
/d
ay
PP
T-
ty
pe
3
0
m
g/
kg
/d
ay
PP
D
-ty
pe
10
m
g/
kg
/d
ay
PP
D
-ty
pe
3
0
m
g/
kg
/d
ay
(e)
0
1
2
3
4
W
ei
gh
t o
f k
id
ne
ys
 (g
)
N
or
m
al
D
ia
be
te
s
In
su
lin
 in
je
ct
ed
 co
nt
ro
l
PP
T-
ty
pe
10
m
g/
kg
/d
ay
PP
T-
ty
pe
3
0
m
g/
kg
/d
ay
PP
D
-ty
pe
10
m
g/
kg
/d
ay
PP
D
-ty
pe
3
0
m
g/
kg
/d
ay
(f)
Figure 7: Weights of rats (Panel (a)) and weights of adrenal gland (Panel (b)), liver (Panel (c)), pancreas (Panel (d)), hearts (Panel (e)), and
kidneys (Panel (f)). The insulin injected control group is slightly heavier than other groups. Results were expressed as the mean ± standard
error; ∗𝑃 < 0.05 for the indicated comparisons versus diabetic group.
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Figure 8: Comparison of different atherosclerosis related-gene expressions on adhesionmolecules (Panel (a)), macrophages (Panel (b)), lipid
metabolism (Panel (c)), smooth muscle cells proliferation and migration (Panel (d)), extracellular matrix (Panel (e)), and apoptosis (Panel
(f)) by PCR array analysis. The PPD and PPT groups were fed with PPD-type and PPT-type of ginseng extract at dosage of 30/mg/kg/day,
respectively. The fold change for normal control was set at 1.
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ginsenosides can lower both triglyceride and total cholesterol
level. In contrast, our results demonstrated a decrease in
only the triglyceride level by using a lower dosage of ginseng
extract.Therefore, we believe that ginsengmay have potential
therapeutic effects on elevated lipid levels and this effect may
be dose dependent.
Although glucose level is not lowered in all ginseng-fed
diabetic groups, PPT-type ginseng extract fed at a dose of
30mg/kg/day decreased the level of glycation end products in
diabetic rats (Figure 4). Glycation end-product can be formed
exogenously by heating or cooking or endogenously through
normal aging or accelerated formation under diabetic con-
ditions. The glycation process yields two different products:
early and advanced glycation endproducts (AGEs). Recent
finding shows advanced glycation end products formed
on haemoglobin and HbA1c, which is a well-established
important indicator for glycaemia monitoring.The advanced
glycation end products that accumulate in vascular tissues
are likely related to alterations in the connective tissue
composition of the microvascular wall, which results in
increased tissue rigidity [11]. During the pathogenesis of
diabetes, endothelial cells intake more glucose [35, 36] and
in turn increase the proton gradient and eventually produce
reactive oxygen species and damaged DNA and more glyca-
tion end products will be produced. In other words, lower
levels of advanced glycation end products usually show less
hyperglycemic damages.
Biomarkers for accurately predicting clinical outcome
and assessing disease risk and progression would greatly
facilitate cardiovascular disease diagnosis and therapy. Find-
ing the right balance between safety and efficacy of ther-
apeutic methods probably requires assessing a variety of
anti-inflammatory mechanisms and so forth [37]. Figure 8
showed a panel of atherosclerosis genes (including genes
related to adhesion molecules, inflammation, vascular cell
proliferation, and migration) which are downregulated. The
findings may bring beneficial therapeutic implications to the
vascular complications in diabetes. However, the underly-
ing mechanisms, for example, increased lipid metabolism
but observable increased amount of visceral adipose tissue,
remain to be determined.
5. Conclusion
Ancient pieces of literature Shennong Ben Cao Jing and Kai
Bao Ben Cao have mentioned the potential antiobesity and
antidiabetic effects of Panax ginseng.Here, our present study
proves that the endothelium-dependent relaxation can be
impaired by diabetes mellitus and the damage can be pro-
tected by feeding with ginseng extracts (both PPD-type and
PPT-type). Furthermore, the PCR array result reveals that
ginsengmay exert endothelial protection effect by downregu-
lating the gene expressions of adhesionmolecules, inflamma-
tory cytokines, and chemokines. The protective mechanisms
may partially due to lowering of serum triglyceride levels
or alternating atherosclerosis-related and lipid-related gene
expressions, which may result in anti-inflammation and
endothelial cell protection. Therefore, further studies would
be required to differentiate the protective mechanisms by
individual ginsenosides in the future.
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